Triglyceride-Glucose Index Linked to Cognitive Deficits in Depression and Diabetes

The Metabolic and Inflammatory Intersection of Cognitive Decline

Cognitive impairment is a recognized core feature of major depressive disorder, frequently persisting even after mood symptoms have remitted [1, 2]. These deficits in executive function, processing speed, and memory significantly hinder a patient's ability to return to baseline psychosocial functioning [3, 4]. When depression is comorbid with metabolic disorders such as type 2 diabetes mellitus, the risk of accelerated cognitive decline and progression to neurodegenerative disease increases substantially [5]. While various pharmacological and lifestyle interventions have been explored to address these deficits, identifying reliable biomarkers for early detection remains a clinical priority [6, 7]. A new study published in the Journal of Affective Disorders offers insights into how specific metabolic indices and inflammatory pathways interact to drive cognitive dysfunction in this high-risk population, suggesting that insulin resistance and systemic inflammation are key contributors to neurological decline.

High Prevalence of Cognitive Dysfunction in Comorbid Patients

The researchers conducted a cross-sectional study to evaluate the neurological health of 256 patients who met the diagnostic criteria for both major depressive disorder and type 2 diabetes mellitus. This specific patient population represents a significant clinical challenge, as the metabolic disturbances of diabetes often exacerbate the cognitive and emotional symptoms of depression. To quantify cognitive performance, the study employed the Montreal Cognitive Assessment, a widely used screening instrument that evaluates multiple domains including executive function, attention, and delayed recall. The researchers established a rigorous threshold for their analysis, where cognitive impairment was defined as a Montreal Cognitive Assessment score of less than 26. This standardized cutoff allowed for a clear differentiation between patients with relatively preserved cognitive function and those experiencing clinically relevant deficits. The results of the assessment demonstrated a substantial burden of neurological symptoms among the participants, as cognitive impairment was present in 59.37% of the 256 participants. For the practicing clinician, this high prevalence rate emphasizes the necessity of routine cognitive screening in patients who present with both metabolic and psychiatric diagnoses, as these deficits can significantly impact a patient's ability to manage complex medication regimens and maintain self-care protocols.

The Triglyceride-Glucose Index as a Metabolic Indicator

To better understand the metabolic drivers of neurological decline, the researchers focused on the triglyceride-glucose (TyG) index, which served as a surrogate marker of insulin resistance. The TyG index is a clinical calculation derived from fasting triglyceride and glucose levels used to estimate systemic insulin sensitivity, offering a more accessible alternative to the hyperinsulinemic-euglycemic clamp. In the study population of 256 patients, the researchers observed that metabolic health was closely tied to cognitive status. Specifically, patients with cognitive impairment had higher TyG index levels compared to those without impairment (P < 0.001), suggesting that the severity of insulin resistance may be a key indicator of neurological vulnerability. The strength of this metabolic-cognitive link was further quantified through multivariable logistic regression, which adjusted for potential confounding variables to isolate the impact of metabolic status. The analysis demonstrated that the triglyceride-glucose index was independently associated with cognitive impairment, yielding an odds ratio (OR) of 2.87 (95% CI: 1.68-4.91). For the practicing physician, these data suggest that the triglyceride-glucose index may function as a valuable clinical tool for identifying patients at the highest risk for cognitive deficits, allowing for more targeted monitoring in the management of comorbid metabolic and psychiatric disease.

Inflammatory Mediators of Cognitive Risk

To investigate the biological pathways connecting metabolic dysfunction to neurological decline, the researchers evaluated several peripheral inflammatory markers, specifically C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). These biomarkers serve as systemic indicators of the chronic, low-grade inflammation often observed in both metabolic and psychiatric disorders. In this cohort, those who met the criteria for cognitive impairment exhibited significantly higher levels of CRP, IL-6, and TNF-alpha compared to their cognitively intact counterparts (all P < 0.001). The study further established a direct statistical link between insulin resistance and this systemic immune response, as the triglyceride-glucose index correlated positively with CRP, IL-6, and TNF-alpha (r = 0.35 to 0.42). To determine if this inflammation was a primary driver of cognitive loss, the authors performed a mediation analysis, which is a statistical method used to identify the mechanism through which an independent variable affects a dependent variable. The results showed that peripheral inflammation statistically mediated 28.41% of the association between the triglyceride-glucose index and cognition. For the clinician, these data clarify that while insulin resistance has a direct impact on the brain, nearly one-third of its negative effect on cognitive function is channeled through systemic inflammatory pathways, highlighting potential secondary targets for therapeutic intervention.

A Pathway to Alzheimer's Disease Pathology

To evaluate whether metabolic and inflammatory stress might be driving neurodegenerative processes, the researchers measured plasma biomarkers associated with Alzheimer's disease, specifically the amyloid-beta 42/40 (Aβ42/40) ratio and phosphorylated tau 217 (p-tau217). These molecules serve as peripheral indicators of protein misfolding and neuronal damage within the central nervous system. The study found that patients with cognitive impairment showed a significantly lower Aβ42/40 ratio and higher p-tau217 levels (P < 0.001), suggesting that the metabolic burden of comorbid depression and diabetes may accelerate the accumulation of pathological tau proteins. The researchers utilized a serial mediation analysis, which is a statistical model that explores a sequence of biological events where one factor triggers another, eventually leading to a clinical outcome. This analysis suggested an indirect association where a high triglyceride-glucose index leads to systemic inflammation, which in turn correlates with elevated p-tau217 levels (beta = 0.10, 95% CI: 0.03-0.22). This specific serial mediation pathway involving inflammation and p-tau217 accounted for 12% of the total association between the triglyceride-glucose index and cognition. For the practicing clinician, these findings indicate that the triglyceride-glucose index may serve as an accessible tool for identifying patients at risk for neurodegenerative progression, as it reflects a cascade of immunometabolic changes that ultimately impact brain health.

References

1. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: A meta-analysis and review.. Psychological Bulletin. 2012. doi:10.1037/a0028727

2. Rhee TG, Shim SR, Manning KJ, et al. Neuropsychological Assessments of Cognitive Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis with Meta-Regression.. Psychotherapy and psychosomatics. 2024. doi:10.1159/000535665

3. Ge J, Wang Q, Wang S, Xiong X, Zhai Y. Optimal dose and type of exercise to improve cognitive function in adults with major depressive disorder: a systematic review and Bayesian model-based network meta-analysis.. Frontiers in public health. 2025. doi:10.3389/fpubh.2025.1662778

4. Little B, Anwyll M, Norsworthy L, Corbett L, Schultz-Froggatt M, Gallagher P. Processing speed and sustained attention in bipolar disorder and major depressive disorder: A systematic review and meta-analysis.. Bipolar disorders. 2024. doi:10.1111/bdi.13396

5. Innes KE, Selfe T. Yoga for Adults with Type 2 Diabetes: A Systematic Review of Controlled Trials. Journal of Diabetes Research. 2015. doi:10.1155/2016/6979370

6. Huang I, Chang T, Chen C, Sung J. Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. The international journal of neuropsychopharmacology. 2022. doi:10.1093/ijnp/pyac054

7. Zheng W, Xiang Y, Ungvari GS, et al. Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials.. Shanghai archives of psychiatry. 2016. doi:10.11919/j.issn.1002-0829.216003